Table 1 Clinical characteristics of patients who received one-shot CDDP via HAI plus RT
Characteristics | Median (range) or number of patients |
|---|---|
Age (years) | 69.5 (40–85) |
Gender (male/female) | 28/4 |
ECOG-Performance Status (0/1) | 25/7 |
Etiology (HBV/HCV/HBV + HCV/other) | 9/10/1/12 |
Total bilirubin (mg/dL) | 0.9 (0.4–1.5) |
Albumin (g/dL) | 3.5 (2.6–4.6) |
Prothrombin consumption test (%) | 86.0 (6.2–111) |
Child–Pugh score (5/6/7) | 9/10/13 |
ALBI score |  − 2.17 (− 3.24– − 1.28) |
mALBI grade (1/2a/2b/3) | 5/7/19/1 |
Size of liver tumor (mm) | 103.2 (36–185) |
Number of intrahepatic tumors (< 4/ ≥ 4) | 18/14 |
Relative tumor volume in the liver (< 50%/ ≥ 50%) | 19/13 |
Vp (3/4) | 13/15 |
Vv (0/1/2/3) | 27/1/1/3 |
Extrahepatic spread (without/with) | 22/10 |
HCC stage (III/IVa/IVb)a | 4/6/22 |
BCLC stage (A/B/C) | 0/0/32 |
Alpha-fetoprotein (ng/mL) | 713.2 (1.3–3,686,000) |
Des-γ-carboxy prothrombin (mAU/mL) | 10,039 (36–327,600) |
Additional systemic therapy (with/without) | 23/9 |